LMNA Gene Restrictive Dermopathy Lethal Genetic Test
Welcome to DNA Labs UAE, where we offer the LMNA Gene Restrictive Dermopathy Lethal Genetic Test. This blog post will provide you with all the necessary information about this test, including its components, price, sample condition, report delivery time, method, test type, referring doctor, and pre-test information.
Test Name: LMNA Gene Restrictive Dermopathy Lethal Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Osteology Dermatology Immunology Disorders
Doctor: Dermatologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for LMNA Gene Restrictive Dermopathy Lethal NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LMNA Gene Restrictive Dermopathy Lethal NGS Genetic DNA Test gene LMNA
Test Details
Restrictive dermopathy is a rare genetic disorder characterized by extremely tight, thick, and rigid skin that restricts movement and growth. It is caused by mutations in the LMNA gene, which provides instructions for making a protein called lamin A/C. Lamin A/C is involved in maintaining the structure and function of the cell nucleus.
NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, providing a comprehensive view of an individual’s genetic makeup. In the case of restrictive dermopathy, an NGS genetic test can be used to identify mutations in the LMNA gene that are responsible for the disorder.
A lethal NGS genetic test specifically refers to testing for severe or lethal variants of a particular gene. In the case of restrictive dermopathy, the term “lethal” indicates that the identified mutations in the LMNA gene are associated with a severe form of the disorder that is often fatal before or shortly after birth.
By performing an NGS genetic test for LMNA mutations, healthcare professionals can provide an accurate diagnosis of restrictive dermopathy and offer appropriate genetic counseling and management options for affected individuals and their families.
| Test Name | LMNA Gene Restrictive dermopathy lethal Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Osteology Dermatology Immunology Disorders |
| Doctor | Dermatologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for LMNA Gene Restrictive dermopathy, lethal NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LMNA Gene Restrictive dermopathy, lethal NGS Genetic DNA Test gene LMNA |
| Test Details |
Restrictive dermopathy is a rare genetic disorder characterized by extremely tight, thick, and rigid skin that restricts movement and growth. It is caused by mutations in the LMNA gene, which provides instructions for making a protein called lamin A/C. Lamin A/C is involved in maintaining the structure and function of the cell nucleus. NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, providing a comprehensive view of an individual’s genetic makeup. In the case of restrictive dermopathy, an NGS genetic test can be used to identify mutations in the LMNA gene that are responsible for the disorder. A lethal NGS genetic test specifically refers to testing for severe or lethal variants of a particular gene. In the case of restrictive dermopathy, the term “lethal” indicates that the identified mutations in the LMNA gene are associated with a severe form of the disorder that is often fatal before or shortly after birth. By performing an NGS genetic test for LMNA mutations, healthcare professionals can provide an accurate diagnosis of restrictive dermopathy and offer appropriate genetic counseling and management options for affected individuals and their families. |
